DOI:
10.1055/s-00046090
Allgemeinmedizin up2date
LinksClose Window
References
Smith JA, Kitt MM, Morice AH. et al.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Lancet Resp Med 2020;
8: 775-785
DOI: 10.1016/S2213-2600(19)30471-0. (PMID: 32109425)
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.